The cause for the lockdown is the identification of a new variant of the Covid-19 virus. This strain is said to spread much faster and already accounts for more than 60% of new infections in London. As such, and again quoting Johnson, “when the virus changes its method of attack, we must change our method of defense.”
The new variant may also raise questions about treatments and herd immunity even as remarkable progress is made on vaccines. There is yet no convincing evidence, one way or the other, on whether the new variant alters the course of the disease. Nor is there compelling evidence, either way, of whether it changes immunity responses.
The immediate economic impact will be an even bigger contraction as more people are less able — because of stricter restrictions — or willing — because of greater health concerns — to interact economically. This more pronounced double-dip recession for the U.K. increases the risk of “scarring,” in which short-term problems become longer-term structural impediments to dynamic supply and demand responses.
The new variant also sheds a much brighter spotlight on another issue — that of tighter restrictions on the internal and cross-border travel of people and, perhaps, also some goods.
With four tiers of restrictions in operation throughout England, will the government confront a decision within the next few weeks between tightening restrictions within the existing regime or perhaps imposing a third nationwide lockdown? And how will other countries react to a new variant? Will they follow the earlier examples of Australia and New Zealand and effectively close their borders to non-citizens?
This worsened economic outlook for the global economy in the short term is accentuated by what’s happening elsewhere in the world. Certain countries that had been model managers of the pandemic such as Germany and South Korea find themselves facing more challenging circumstances. South Africa is also said to have identified cases of the new Covid variant, suggesting that other countries may also have to impose additional restrictions because of this virus mutation. Yet others that have struggled more, such as the U.S., are in an even worse place.
I am writing this column from California, where the average daily infection rate has spiked to 50,000, hospitalizations have soared and, with no ICU beds available in the southern part of the state, deaths are tragically on the rise. Yet there seems to be even more polarization among Californians on how state and local governments should react. This divide is also playing out in vast differences in compliance with existing guidelines, all of which undermine the possibility of timely policy reactions and appropriately healthy collective actions.
As wonderful as the encouraging news about vaccines is, we should not lose sight of the tragic severity of the immediate outlook. Absent a more timely and holistic response on the part of both the public and private sectors, we risk a lot more damage — both temporary and durable — in the remaining voyage to herd immunity and the related return to better public health and more normal economic and social interactions.
